Idarubicin Accord Healthcare (Idarubicin Hydrochloride)

Idarubicin exerts its antineoplastic effect by intercalating into DNA and inhibiting the enzyme topoisomerase II, which is essential for DNA replication and transcription. This blockade creates double‑strand DNA breaks, leading to apoptosis of malignant cells. The drug also generates free radicals that further damage cellular components, amplifying its cytotoxic activity.

The dose of idarubicin is individualized by the prescribing oncologist based on factors such as the specific leukemia subtype, disease stage, patient body surface area, renal and hepatic function, and prior treatment history. Clinical guidelines provide dosing ranges, but the exact regimen is set by the treating physician to optimise efficacy while managing toxicity.

Idarubicin is classified as contraindicated during pregnancy because it can cross the placenta and cause fetal harm, including teratogenic effects and embryotoxicity. Breastfeeding is also discouraged, as the drug may be excreted in milk and affect the infant. Use is only considered if the potential benefit to the mother outweighs the risks to the fetus or child, and only under specialist supervision.

To place an order, visit the product page for Idarubicin Accord Healthcare on the GNH India website (gnhindia.com) and submit an enquiry with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details—including cold‑chain handling if needed—and assist with any required import documentation.

Idarubicin is structurally related to other anthracyclines such as doxorubicin and daunorubicin but possesses a higher lipophilicity, which enhances cellular uptake and may provide greater potency against certain leukemias. Compared with doxorubicin, idarubicin often demonstrates a more favorable cardiac safety profile at equivalent doses, though all anthracyclines share risks of cardiotoxicity and myelosuppression. Choice of agent depends on disease characteristics, prior therapy, and individual patient risk factors.

Idarubicin Accord Healthcare should be stored refrigerated at 2 °C to 8 °C (36 °F to 46 °F). The product must be kept in its original packaging to protect it from light, and it should never be frozen or shaken. If temperature excursions occur, the product should be inspected for any changes in appearance before use, and any compromised vials must be discarded according to local regulations.

Idarubicin is given as an intravenous infusion, typically diluted in a compatible solution such as 5 % dextrose or normal saline. The infusion rate and duration are determined by the prescribing protocol, often over 30 minutes to several hours, and may be administered on specific days within a chemotherapy cycle. Administration should be performed by qualified healthcare professionals in a setting equipped to monitor for infusion‑related reactions and cardiac function.

The most critical risks associated with idarubicin include cardiotoxicity, which can manifest as reduced left‑ventricular ejection fraction or congestive heart failure, and severe myelosuppression leading to neutropenic infections, anemia, or bleeding. Additional serious concerns are the development of secondary malignancies and acute pulmonary toxicity. Patients should undergo regular cardiac assessments, complete blood counts, and close clinical monitoring to detect these complications early.

Idarubicin is contraindicated in individuals with known hypersensitivity to idarubicin or any anthracycline component, those with pre‑existing severe cardiac disease, uncontrolled infections, or significant hepatic impairment that cannot be managed. Pregnant women and nursing mothers should avoid the drug unless the therapeutic benefit justifies the potential risk. Patients with a history of severe arrhythmias or who are receiving other cardiotoxic agents should also be evaluated carefully before treatment.